Group Gp Lp Column III Buys 49,463 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYAGet Rating) major shareholder Group Gp Lp Column III purchased 49,463 shares of the business’s stock in a transaction dated Tuesday, January 17th. The stock was bought at an average price of $2.49 per share, with a total value of $123,162.87. Following the acquisition, the insider now directly owns 9,664,847 shares in the company, valued at $24,065,469.03. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Tenaya Therapeutics Price Performance

Tenaya Therapeutics stock opened at $2.86 on Friday. Tenaya Therapeutics, Inc. has a 12-month low of $1.64 and a 12-month high of $16.17. The stock has a market capitalization of $118.33 million, a P/E ratio of -1.02 and a beta of 1.61. The firm’s 50-day moving average is $2.28 and its two-hundred day moving average is $3.40.

Tenaya Therapeutics (NASDAQ:TNYAGet Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.10). As a group, analysts forecast that Tenaya Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Investors Weigh In On Tenaya Therapeutics

Several hedge funds have recently modified their holdings of TNYA. Barclays PLC boosted its stake in shares of Tenaya Therapeutics by 539.1% during the 3rd quarter. Barclays PLC now owns 8,960 shares of the company’s stock worth $26,000 after purchasing an additional 7,558 shares during the last quarter. Amalgamated Bank acquired a new stake in shares of Tenaya Therapeutics in the first quarter worth approximately $29,000. Balyasny Asset Management LLC acquired a new stake in shares of Tenaya Therapeutics in the third quarter worth approximately $29,000. BNP Paribas Arbitrage SNC acquired a new stake in shares of Tenaya Therapeutics in the third quarter worth approximately $43,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Tenaya Therapeutics in the second quarter worth approximately $59,000.

Analyst Ratings Changes

A number of brokerages recently commented on TNYA. Canaccord Genuity Group began coverage on shares of Tenaya Therapeutics in a research note on Monday, November 7th. They issued a “buy” rating on the stock. Chardan Capital lowered their price objective on shares of Tenaya Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. Finally, Canaccord Genuity Group began coverage on shares of Tenaya Therapeutics in a research note on Tuesday, November 8th. They issued a “buy” rating and a $21.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tenaya Therapeutics has an average rating of “Buy” and an average price target of $24.67.

Tenaya Therapeutics Company Profile

(Get Rating)

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).

Read More

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.